Mode
Text Size
Log in / Sign up
Phase 3 Completed N=606 Randomized Double-blind Treatment

Lubiprostone in Children With Functional Constipation

Constipation - Functional
Source: ClinicalTrials.gov NCT02042183 ↗
Enrolled (actual)
606
Serious AEs
3.0%
Results posted
Jul 2020
Primary outcomePrimary: Number of Participants Classified as Overall Responders at Week 12 — 76; 28 Participants — p=0.1609
◆ Published Evidence
Established
51citations · ~13 / year
Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Open access · Likely link

Summary

Study to determine if children (6-17 years old) with functional constipation will respond to being treated with lubiprostone for 12 weeks.

Linked Publications

  • Lubiprostone for Pediatric Functional Constipation: Randomized, Controlled, Double-Blind Study With Long-term Extension.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · 51 citations · Open access · Likely link

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants Classified as Overall Responders at Week 12
76; 28 0.1609
SECONDARY
Mean Number of SBMs Observed Each Week for 12 Weeks
1.40; 1.42; 2.65; 2.50; 2.68; 2.69

Eligibility Criteria

Inclusion Criteria

  • Medically-confirmed diagnosis of Functional Constipation per Rome III Diagnostic Criteria for Childhood Functional Constipation
  • At least 6 years of age but less than 18 years of age at the time of randomisation
  • Only stable dose of selective serotonin re-uptake inhibitors (SSRIs), serotonin-specific reuptake inhibitor (SNRIs), or monoamine oxidase inhibitors (MAO) inhibitors are allowed if subject is taking antidepressants

Exclusion Criteria

  • Any gastrointestinal (GI) condition, other than constipation and/or irritable bowel syndrome (IBS), affecting GI motility or defecation
  • Untreated faecal impaction at the time of screening
  • Medical/surgical condition that might interfere with the absorption, distribution, metabolism, or excretion of the study medication
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02042183) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search